| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FON.13.25 |
| P698 | PubMed publication ID | 23647300 |
| P2093 | author name string | Jie Pan | |
| Pan Chi | |||
| Shaotang Li | |||
| Xingrong Lu | |||
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma | Q28185284 | ||
| Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues | Q28202997 | ||
| Molecular cloning and expression of a variant form of hippostasin/KLK11 in prostate | Q28204474 | ||
| Alternative splicing isoforms of hippostasin (PRSS20/KLK11) in prostate cancer cell lines | Q28215890 | ||
| Human colorectal carcinogenesis is associated with deregulation of homeobox gene expression | Q28236431 | ||
| Expression of the human kallikrein genes 10 (KLK10) and 11 (KLK11) in cancerous and non-cancerous lung tissues | Q28248492 | ||
| Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer | Q28250722 | ||
| Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer | Q28257940 | ||
| Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 | ||
| Pharmacogenetics and adverse drug reactions | Q34088287 | ||
| A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. | Q34282412 | ||
| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 | ||
| Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide | Q34609485 | ||
| Lessons from phase III clinical trials on anti-VEGF therapy for cancer | Q36366446 | ||
| Human tissue kallikreins: the cancer biomarker family | Q36726851 | ||
| A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? | Q37497669 | ||
| Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes | Q38423849 | ||
| Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy | Q43406715 | ||
| Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy | Q43932425 | ||
| Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer | Q44033535 | ||
| Association of TMPRSS2 and KLK11 gene expression levels with clinical progression of human prostate cancer | Q46109463 | ||
| Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial | Q46570394 | ||
| ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. | Q46689409 | ||
| A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma | Q46721143 | ||
| Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line | Q46856662 | ||
| Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. | Q53353721 | ||
| Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. | Q53577396 | ||
| Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. | Q55043363 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 727-736 | |
| P577 | publication date | 2013-05-01 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Identification of HOXB8 and KLK11 expression levels as potential biomarkers to predict the effects of FOLFOX4 chemotherapy | |
| P478 | volume | 9 |
| Q91583137 | A panel of Transcription factors identified by data mining can predict the prognosis of head and neck squamous cell carcinoma |
| Q57790170 | Distinct esophageal adenocarcinoma molecular subtype has subtype-specific gene expression and mutation patterns |
| Q90697853 | FBXW4 Acts as a Protector of FOLFOX-Based Chemotherapy in Metastatic Colorectal Cancer Identified by Co-Expression Network Analysis |
| Q60921419 | HOXB8 enhances the proliferation and metastasis of colorectal cancer cells by promoting EMT via STAT3 activation |
| Q64916535 | Identification of a 13-gene-based classifier as a potential biomarker to predict the effects of fluorouracil-based chemotherapy in colorectal cancer. |
| Q36562337 | Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues |
| Q47148210 | Immunological landscape of consensus clusters in colorectal cancer |
| Q61810539 | Knock-Down of HOXB8 Prohibits Proliferation and Migration of Colorectal Cancer Cells via Wnt/β-Catenin Signaling Pathway |
| Q37406381 | Knockdown of KLK11 inhibits cell proliferation and increases oxaliplatin sensitivity in human colorectal cancer |
| Q92938044 | Overexpressed CES2 has prognostic value in CRC and knockdown CES2 reverses L-OHP-resistance in CRC cells by inhibition of the PI3K signaling pathway |
| Q92684359 | Response prediction to oxaliplatin plus 5-fluorouracil chemotherapy in patients with colorectal cancer using a four-protein immunohistochemical model |
Search more.